Liminal BioSciences Inc. (LMNL) News Headlines

▮ More

Date

Headline

9/8/2020 6:05:26 AM Liminal BioSciences Announces Resubmission Of BLA For Ryplazim For Treatment Of Congenital Plasminogen Deficiency

9/8/2020 6:00:00 AM Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital Plasminogen Deficiency (Press Release)

8/24/2020 5:47:03 PM After Market Hours: VivoPower, Arcturus Therapeutics, Tortoise Gain; Liminal, Portland General Slip

8/24/2020 9:52:20 AM Stock Alert: Liminal BioSciences Jumps 45%

8/24/2020 6:50:50 AM Pre-market Movers In Healthcare Sector: SONN, ADMA, THMO, LMNL, KMDA...

8/4/2020 3:31:42 AM ALRN To Report Data In Q4, IMUC Hits New High, VYGR Pulls Out Of ABBV Deal, VNDA To Face FDA In Dec.

7/31/2020 2:50:46 AM PRPO Up 400% As It Readies For Rollout Of COVID-19 Test, LXRX Realigns Business, VRTX Boosts Outlook

7/17/2020 8:00:00 AM Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases (Press Release)

7/7/2020 3:45:41 AM BLU Plunges On RELIEF Data, FDA Places CLLS' Trial On Hold, IMMU Hits New High, OTIC Music To Ears

7/2/2020 1:08:19 AM LMNL Joins COVID-19 Battle, PFE/BNTX Vaccine Data Promising, EVLO On Watch

1/13/2020 7:00:00 AM Liminal BioSciences Outlines Corporate Priorities for 2020 (Press Release)

6/14/2019 3:34:30 AM Prometic Announces Four Abstracts Highlighting Progress In Developing PBI-4050

12/19/2018 7:32:29 AM Prometic Life Sciences Names Simon Best As Interim CEO; Pierre Laurin Has Stepped Down

8/7/2018 7:13:14 AM Prometic Receives Rare Pediatric Disease Designation From FDA For Small Molecule Drug Candidate, PBI-4050

4/30/2018 6:33:39 AM Prometic Reports Positive Clinical Data From IVIG Pivotal Phase 3 Trial; Meets Primary And Secondary Endpoints

4/12/2018 6:34:22 AM Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial

3/28/2018 7:58:32 AM Biotech Stocks Facing FDA Decision In April

3/5/2018 7:09:40 AM Prometic: FDA Grants Rare Pediatric Disease Designation To Inter-Alpha-Inhibitor-Proteins For Necrotizing Enterocolitis

2/16/2018 7:33:17 AM Prometic Announces Publication Of PBI-4050's Novel Antifibrotic Mechanism Of Action In American Journal Of Pathology

7/30/2015 9:17:08 AM RBC Capital Markets Initiates ProMetic Life Sciences Inc. (PLI.TO) At Outperform With C$3.50 Price Target

Older Articles

Liminal Biosciences Inc. (LMNL)